Sun Pharmaceutical Industries Limited has announced that CRISIL Ratings has removed the ‘Rating Watch with Developing Implications’ status from the company’s long-term bank facilities. The top-tier rating of ‘CRISIL AAA’ has been reaffirmed with a stable outlook. This follows an earlier communication on May 7, 2026, where the rating was placed under watch. The company’s announcement on April 27, 2026, led to this review.
Credit Rating Update for Sun Pharma
Sun Pharmaceutical Industries Limited today announced an update on its credit rating. Following a review, CRISIL Ratings Limited has removed the ‘Rating Watch with Developing Implications’ status that was previously placed on the company’s long-term bank facilities.
Reaffirmation of ‘CRISIL AAA/Stable’ Rating
The agency has reaffirmed the rating assigned to Sun Pharmaceutical Industries Limited’s long-term bank facilities at the highest category, ‘CRISIL AAA’. Crucially, the rating now carries a ‘Stable’ outlook. This reassures investors about the company’s robust financial health and its ability to meet its financial obligations.
Background of the Rating Watch
This development is in reference to a prior communication dated 07 May 2026. At that time, CRISIL had reaffirmed the ‘CRISIL AAA’ rating but had placed it on ‘Rating Watch with Developing Implications’. This action was triggered by the company’s announcement on 27 April 2026, the implications of which have now been assessed, leading to the removal of the watch and the stable outlook.
Source: BSE
